Vifor Pharma Licenses Marketing Rights to ChemoCentryx's CCX168 in Europe, Canada, Mexico, Central and S. America, S. Korea; ChemoCentryx to Receive Upfront Payment of $60M, Equity Investment of $25M @$7.50/Share